



Pfizer Announces *Cachexia in Cancer – Educational Needs Assessment Competitive Grant Program - internal Pfizer review process*

I. Background

Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.

For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.

II. Eligibility

Geographic Scope:	United States, Canada, Japan, Italy, UK, Spain, Germany, and/or France
Applicant Eligibility Criteria	<ul style="list-style-type: none"> The following may apply: medical, dental, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement. If the project involves multiple departments within an institution and/or between different institutions / organizations / associations. all institutions must have a relevant role and the requesting organization must have a key role in the project. For projects offering continuing education credit, the requesting organization must be accredited.

III. Requirements

Date RFP Issued	March 6, 2020
Clinical Area	Cachexia in cancer
General Area of Interest for this RFP:	<p>It is our intent to provide an independent grant to an organization or organizations who will conduct a thorough educational needs assessment in the area of cachexia in cancer.</p> <p>Cachexia is a complex metabolic syndrome characterized by muscle loss with or without loss of fat mass.¹ It is associated with underlying illness and is seen in many chronic conditions, including chronic obstructive pulmonary disease, congestive heart failure, chronic kidney disease and cancer. Cachexia is present in up to half of patients with cancer and in about 80% of patients with advanced cancer.² It adversely affects many cancer patients by inducing progressive weight loss, as well as impairing appetite, physical function and quality of life.³</p> <p>Despite its prevalence, cachexia in cancer is a complex condition that is poorly understood. Consequently, it is underdiagnosed and in cancer patients who are identified as having cachexia, a lack of effective treatment options means physicians are not able to help meet patients' needs.⁴</p> <p>Pfizer's intent is for the results of the needs assessment to be shared with the entire medical community in order to enhance future medical</p>

	<p>education programs that eliminate barriers and close gaps experienced by HCPs. In addition, the results will be used to inform educational budget planning and future Request for Proposals (RFPs)</p> <p>References:</p> <ol style="list-style-type: none"> 1. Homsí J, Luong D. Symptoms and survival in patients with advanced disease. <i>J Palliat Med.</i> 2007;10(4):904-909. 2. Vagnildhaug OM, Balstad TR, Almberg SS, et al. A cross-sectional study examining the prevalence of cachexia and areas of unmet need in patients with cancer. <i>Support Care Cancer.</i> 2018;26(6):1871-1880. 3. Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. <i>Nat Rev Clin Oncol.</i> 2013;10(2):90-99. 4. Bruggeman AR, Kamal AH, LeBlanc TW et al. Cancer Cachexia: Beyond Weight Loss. <i>Journal of Oncology Practice</i> 2016;12:11, 1163-1171.
Target Audience:	Oncologists, Oncology Palliative Care, Oncology Nurses, Oncology Pharmacists and other members of the cancer care team.
Expected Approximate Monetary Range of Grant Applications:	Individual projects requesting up to \$300,000 USD will be considered.
Key Dates:	<ul style="list-style-type: none"> • RFP release date: March 6, 2020 • Grant Application due date: April 29, 2020 Please note the deadline is midnight Eastern Standard Time (e.g. New York, GMT -5). • Anticipated Grant Award Notification Date: June 1, 2020 • Grants will be distributed following a fully executed agreement. • Anticipated Project Start: June 2020

<p>How to Submit:</p>	<ul style="list-style-type: none"> • Please go to www.cybergrants.com/pfizer/knowledge and sign in. First-time users should click “Create your password”. • In the application: <ul style="list-style-type: none"> ○ For the question “What type of request are you submitting?” select Response to a Request for Proposal (RFP) ○ For the question “Are you replying to a Request for Proposal as part of the Competitive Grant Program?” select Yes ○ Select the following Competitive Grant Program Name: 2020 IM G - Cachexia in Cancer Needs Assessment ○ Select the following Primary Area of Interest: Oncology-Other • Requirements for submission: Complete all required sections of the online application and upload your project proposal (see Appendix) in the General RFP Submission field. • If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page. <p>IMPORTANT: Be advised applications submitted after the due date will not be reviewed by the committee.</p>
<p>Questions:</p>	<ul style="list-style-type: none"> • If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Angelo Carter (angelo.carter@pfizer.com), with the subject line “Cachexia in Cancer”
<p>Mechanism by which Applicants will be Notified:</p>	<ul style="list-style-type: none"> • All applicants will be notified via email by the dates noted above. • Applicants may be asked for additional clarification during the review period.

IV. Terms and Conditions

Please take note every RFP released by Pfizer Global Medical Grants (GMG) is governed by specific terms and conditions. These terms and conditions can be reviewed [here](#).

Appendix A

General RFP Submission Requirements

Project Proposals should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit exclusive of references. Please include the following:

Goals and Objectives	<ul style="list-style-type: none"> Briefly state the overall goal of the project. List the objectives you plan to meet with your project, in terms of learning and expected outcomes.
Needs Assessment for the Project	<ul style="list-style-type: none"> Include a description of your organization's needs assessment for this proposed project which may include a quantitative baseline data summary, initial metrics, or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area.
Target Audience	<ul style="list-style-type: none"> Describe the primary audience(s) targeted for this project. Indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population.
Project Design and Methods	<ul style="list-style-type: none"> Describe the planned project, the educational approach, and the way the planned methods address the established need.
Innovation	<ul style="list-style-type: none"> Explain what measures you have taken to assure that this project is original and does not duplicate other projects or materials already developed. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions.
Evaluation and Outcomes	<ul style="list-style-type: none"> In terms of the metrics used for the needs assessment, describe how your organization will determine if the gap was addressed for the target group. Identify the sources of data your organization anticipates using to make the determination. Describe how your organization is expected to collect and analyze the data. Explain the method used to control for other factors outside this project (e.g., use of a control group or comparison with baseline data). Quantify the amount of change expected from this project in terms the target audience. Describe how your organization will determine if the target audience was fully engaged in the project.
Dissemination Plan	<ul style="list-style-type: none"> Describe how the project may have extended benefit beyond the grant. Will the teaching materials be made available to others to use? Will there be tools or resources that are made publicly available beyond the

	initial project. Describe how the project outcomes might be broadly disseminated.
Anticipated Project Timeline	<ul style="list-style-type: none"> • Provide an anticipated timeline for your project including project start/end dates.
Additional Information	<ul style="list-style-type: none"> • If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here.
Organization Detail	<ul style="list-style-type: none"> • Describe the attributes of the institutions/organizations that will support and facilitate the execution of the project, the leadership of the proposed project, and the specific role of each institution in the proposed project.
Budget Narrative	<ul style="list-style-type: none"> • Please include a budget narrative that describes in greater detail the line items specified in the budget submitted within the application • While estimating your budget please keep the following items in mind: <ul style="list-style-type: none"> ○ Independent Medical Education Grants awarded by GMG cannot be used to purchase therapeutic assets (prescription or non-prescription). ○ Overhead rates of up to 28% of the total proposed project budget may be supported by Pfizer.